Kailera Therapeutics, Inc. (KLRA) stock
KLRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026
$12.20−0.37 (-2.94%)
Close on Nov 17, 2026Market cap $1.58BP/E –Yield –
Kailera Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$106.24M | – |
| Q2 FY2026 | Jun 30, 2026 | -$121.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$84.56M | – |
| Q3 FY2025 | Sep 30, 2025 | -$40.05M | – |
| Q2 FY2025 | Jun 30, 2025 | -$30.59M | – |
| Q1 FY2025 | Mar 31, 2025 | -$20.40M | – |
See a number that looks wrong?